<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01741831</url>
  </required_header>
  <id_info>
    <org_study_id>CR100805</org_study_id>
    <secondary_id>TMC114HIV4074</secondary_id>
    <secondary_id>Prezista PMS</secondary_id>
    <secondary_id>DRV-C-11-KR-001-V06</secondary_id>
    <nct_id>NCT01741831</nct_id>
  </id_info>
  <brief_title>A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista</brief_title>
  <official_title>Regulatory Post Marketing Surveillance of Prezista 400mg Tablet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Korea, Ltd., Korea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Korea, Ltd., Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety data of darunavir in a natural clinical
      practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-interventional (a scientific study to make a clear and easy understanding of
      the cause and effect relationship), prospective (in which the participants are first
      identified and then followed forward as time passes), consecutive survey for collecting
      safety and efficacy data of darunavir in treatment of Acquired Immune Deficiency Syndrome
      (AIDS) in a natural clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 30 days from end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with viral load</measure>
    <time_frame>Screening, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with CD4 T-cell count</measure>
    <time_frame>Screening, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">225</enrollment>
  <condition>Acquired Immune Deficiency Syndrome</condition>
  <arm_group>
    <arm_group_label>Darunavir</arm_group_label>
    <description>Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking darunavir as per recommended doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.</description>
    <arm_group_label>Darunavir</arm_group_label>
    <other_name>Prezista</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include patients who are diagnosed with Acquired Immune
        Deficiency Syndrome (AIDS), and who are prescribed with darunavir for treatment of AIDS.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are prescribed with darunavir for treatment of Acquired Immune Deficiency
             Syndrome (AIDS)

        Exclusion Criteria:

          -  Known hypersensitivity to Prezista

          -  Prezista coadministered with medicinal products that are highly dependent on CYP3A for
             clearance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Korea, Ltd., Korea Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Korea, Ltd., Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Dae-Gu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acquired Immune Deficiency Syndrome</keyword>
  <keyword>AIDS</keyword>
  <keyword>TMC114</keyword>
  <keyword>Darunavir</keyword>
  <keyword>Prezista</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

